Gastrointestinal (GI) Cancers are common diseases worldwide. About 400,000 patients are diagnosed with Esophageal Cancer worldwide each year and nearly 330,000 die for this disease. Roughly 870,000 patients are newly diagnosed each year with Gastric Cancer and over 600,000 die from the disease each year. 940,000 new cases of Colorectal Cancer are diagnosed annually and 490,000 patients die from this disease.
Management options for patients with GI Cancer have undergone dramatic changes in the past decade. New cytotoxic agents, novel targeted agents, surgical and ablative options, as well as a new array of supportative medications have shown substantial progress. With the increased number of therapeutic options from which to choose, the Clinician is better placed to offer effective therapy. At the same time the Clinician is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the options for treatment today and in the future.
Gastrointestinal Malignancies provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers evidence-based recommendations. The editors and authors are leaders in their fields. The chapters update the current screening tools for Colon Cancers, assessment of predictive markers such as k-Ras and BRAF in the management of Colon Cancer as well as the state-of-the-art for use of both cytotoxic chemotherapy and the incorporation of newer biological therapies.
About the series:
Emerging Cancer Therapeutics is an invited review publication providing a thorough analysis of key clinical research related to Cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both Solid and Hematologic Malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.
Features of the Emerging Cancer Therapeutics include:
Editorial board of nationally recognised experts across the spectrum of Cancer therapeutics
In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer therapeutics
Issues edited by an authority in specific subject area
Focuses on major topics in Cancer therapeutics with in-depth articles covering advances in clinical and translational research developments as well as clinical applications and experience
Emphasises multidisciplinary approaches to research and practice
Editor-in-chief: Jame Abraham
